- Report
- August 2025
- 195 Pages
Global
From €3161EUR$3,545USD£2,743GBP
€3512EUR$3,939USD£3,048GBP
- Report
- August 2025
- 187 Pages
Global
From €3161EUR$3,545USD£2,743GBP
€3512EUR$3,939USD£3,048GBP
- Report
- August 2025
- 198 Pages
Global
From €3161EUR$3,545USD£2,743GBP
€3512EUR$3,939USD£3,048GBP
- Report
- October 2025
- 188 Pages
Global
From €3161EUR$3,545USD£2,743GBP
€3512EUR$3,939USD£3,048GBP
- Report
- October 2025
- 269 Pages
Global
From €5216EUR$5,850USD£4,527GBP
- Report
- February 2025
- 200 Pages
Global
From €4003EUR$4,490USD£3,474GBP
- Report
- April 2025
- 200 Pages
Global
From €7088EUR$7,950USD£6,152GBP
- Report
- September 2025
- 150 Pages
Global
From €2674EUR$2,999USD£2,321GBP
- Report
- June 2025
- 200 Pages
Global
From €4454EUR$4,995USD£3,865GBP
- Report
- October 2024
- 200 Pages
Global
From €3344EUR$3,750USD£2,902GBP
- Report
- March 2024
- 200 Pages
Global
From €3700EUR$4,150USD£3,211GBP
- Report
- May 2024
- 134 Pages
Global
From €5795EUR$6,499USD£5,029GBP
From €3968EUR$4,450USD£3,443GBP

Rifaximin is a semi-synthetic antibiotic used to treat gastrointestinal diseases. It is used to treat travelers' diarrhea, irritable bowel syndrome with diarrhea, and hepatic encephalopathy. Rifaximin is also used to prevent recurrent episodes of hepatic encephalopathy. It is a broad-spectrum antibiotic that is effective against both Gram-positive and Gram-negative bacteria.
Rifaximin is available in both oral and intravenous formulations. The oral formulation is available as tablets, capsules, and granules. The intravenous formulation is available as a solution for injection. Rifaximin is available in several countries, including the United States, Canada, and Europe.
Rifaximin is a relatively new drug in the gastrointestinal drugs market. It is used to treat a variety of gastrointestinal diseases, and is becoming increasingly popular due to its effectiveness and safety profile.
Some companies in the Rifaximin market include Salix Pharmaceuticals, Inc., Actavis, Inc., and Lupin Pharmaceuticals, Inc. Show Less Read more